JNK3 Is Required for the Cytoprotective Effect of Exendin 4

Ezanno, Hélène; Pawlowski, Valérie; Abdelli, Saida; Boutry, Raphaël; Gmyr, Valéry; Kerr–Conte, Julie; Bonny, Christophe; Pattou, François; Abderrahmani, Amar

doi:10.1155/2014/814854

Cited by 19 publications

(12 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data are consistent with recent studies where GLP-1 or its synthetic analogues (through GLP-1-R) engaged several downstream signaling pathways and exerted pro-survival, proliferative and, anti-apoptotic effects on human/murine islets, endothelial cells and some other tissues. 13,23,24 Also, sustained GLP-1-R activation has been shown to increase small intestine and colonic mucosal epithelium mass in rodents. 25 …”

Section: Discussionmentioning

confidence: 99%

GLP-1 nanomedicine alleviates gut inflammation

Anbazhagan

Thaqi

Priyamvada

et al. 2017

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

The gut hormone, glucagon like peptide-1 (GLP-1) exerts anti-inflammatory effects. However, its clinical use is limited by its short half-life. Previously, we have shown that GLP-1 as a nanomedicine (GLP-1 in sterically stabilized phospholipid micelles, GLP-1-SSM) has increased in vivo stability. The current study was aimed at testing the efficacy of this GLP-1 nanomedicine in alleviating colonic inflammation and associated diarrhea in dextran sodium sulfate (DSS) induced mouse colitis model. Our results show that GLP-1-SSM treatment markedly alleviated the colitis phenotype by reducing the expression of pro-inflammatory cytokine IL-1β, increasing goblet cells and preserving intestinal epithelial architecture in colitis model. Further, GLP-1-SSM alleviated diarrhea (as assessed by luminal fluid) by increasing protein expression of intestinal chloride transporter DRA (down regulated in adenoma). Our results indicate thatGLP-1 nanomedicine may act as a novel therapeutic tool in alleviating gut inflammation and associated diarrhea in inflammatory bowel disease (IBD).

show abstract

Section: Discussionmentioning

confidence: 99%

GLP-1 nanomedicine alleviates gut inflammation

Anbazhagan

Thaqi

Priyamvada

et al. 2017

Nanomedicine: Nanotechnology, Biology and Medicine

View full text Add to dashboard Cite

show abstract

“…Finally, the inhibition of MAPK10 (also named JNK3) in non-diabetic patients could be involved in the development of T2DM. MAPK10 plays a protective role in insulin-secreting cells against death caused by pro-inflammatory cytokines 64 . Since chronic inflammation is a well-recognized feature of obesity-related co-morbidities 65 , our results suggest that MAPK10 inhibition might be related to the impairment of analogous processes in VAT.…”

Section: Discussionmentioning

confidence: 99%

Proteome-wide alterations on adipose tissue from obese patients as age-, diabetes- and gender-specific hallmarks

Gómez-Serrano

Camafeita

García-Santos

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Obesity is a main global health issue and an outstanding cause of morbidity and mortality predisposing to type 2 diabetes (T2DM) and cardiovascular diseases. Huge research efforts focused on gene expression, cellular signalling and metabolism in obesity have improved our understanding of these disorders; nevertheless, to bridge the gap between the regulation of gene expression and changes in signalling/metabolism, protein levels must be assessed. We have extensively analysed visceral adipose tissue from age-, T2DM- and gender-matched obese patients using high-throughput proteomics and systems biology methods to identify new biomarkers for the onset of T2DM in obesity, as well as to gain insight into the influence of aging and gender in these disorders. About 250 proteins showed significant abundance differences in the age, T2DM and gender comparisons. In diabetic patients, remarkable gender-specific hallmarks were discovered regarding redox status, immune response and adipose tissue accumulation. Both aging and T2DM processes were associated with mitochondrial remodelling, albeit through well-differentiated proteome changes. Systems biology analysis highlighted mitochondrial proteins that could play a key role in the age-dependent pathophysiology of T2DM. Our findings could serve as a framework for future research in Translational Medicine directed at improving the quality of life of obese patients.

show abstract

“…Apoptosis was determined by determining mono- and oligonucleosomes in the cytoplasmic fraction by ELISA kit (Roche Molecular Biochemicals) and by scoring cells displaying pyknotic or fragmented nuclei (visualized with Hoechst 33342) [ 36 ]. The counting was performed blind by two different experimenters.…”

Section: Methodsmentioning

confidence: 99%

The Class I Histone Deacetylase Inhibitor MS-275 Prevents Pancreatic Beta Cell Death Induced by Palmitate

Plaisance

Rolland

Gmyr

et al. 2014

Journal of Diabetes Research

Self Cite

View full text Add to dashboard Cite

Elevation of the dietary saturated fatty acid palmitate contributes to the reduction of functional beta cell mass in the pathogenesis of type 2 diabetes. The diabetogenic effect of palmitate is achieved by increasing beta cell death through induction of the endoplasmic reticulum (ER) stress markers including activating transcription factor 3 (Atf3) and CAAT/enhancer-binding protein homologous protein-10 (Chop). In this study, we investigated whether treatment of beta cells with the MS-275, a HDAC1 and HDAC3 activity inhibitor which prevents beta cell death elicited by cytokines, is beneficial for combating beta cell dysfunction caused by palmitate. We show that culture of isolated human islets and MIN6 cells with MS-275 reduced apoptosis evoked by palmitate. The protective effect of MS-275 was associated with the attenuation of the expression of Atf3 and Chop. Silencing of HDAC3, but not of HDAC1, mimicked the effects of MS-275 on the expression of the two ER stress markers and apoptosis. These data point to HDAC3 as a potential drug target for preserving beta cells against lipotoxicity in diabetes.

show abstract

JNK3 Is Required for the Cytoprotective Effect of Exendin 4

Cited by 19 publications

References 37 publications

GLP-1 nanomedicine alleviates gut inflammation

GLP-1 nanomedicine alleviates gut inflammation

Proteome-wide alterations on adipose tissue from obese patients as age-, diabetes- and gender-specific hallmarks

The Class I Histone Deacetylase Inhibitor MS-275 Prevents Pancreatic Beta Cell Death Induced by Palmitate

Contact Info

Product

Resources

About